Publications

BibTex format

@article{Grundmann:2017:10.1016/S1473-3099(16)30257-2,
author = {Grundmann, H and Glasner, C and Albiger, B and Aanensen, DM and Tomlinson, CT and Andrasevi, AT and Cantón, R and Carmeli, Y and Friedrich, AW and Giske, CG and Glupczynski, Y and Gniadkowski, M and Livermore, DM and Nordmann, P and Poirel, L and Rossolini, GM and Seifert, H and Vatopoulos, A and Walsh, T and Woodford, N and Monnet, DL and European, Survey of Carbapenemase-Producing Enterobacteriaceae EuSCAPE Working Group},
doi = {10.1016/S1473-3099(16)30257-2},
journal = {Lancet Infect Dis},
pages = {153--163},
title = {Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.},
url = {http://dx.doi.org/10.1016/S1473-3099(16)30257-2},
volume = {17},
year = {2017}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Gaps in the diagnostic capacity and heterogeneity of national surveillance and reporting standards in Europe make it difficult to contain carbapenemase-producing Enterobacteriaceae. We report the development of a consistent sampling framework and the results of the first structured survey on the occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in European hospitals. METHODS: National expert laboratories recruited hospitals with diagnostic capacities, who collected the first ten carbapenem non-susceptible clinical isolates of K pneumoniae or E coli and ten susceptible same-species comparator isolates and pertinent patient and hospital information. Isolates and data were relayed back to national expert laboratories, which made laboratory-substantiated information available for central analysis. FINDINGS: Between Nov 1, 2013, and April 30, 2014, 455 sentinel hospitals in 36 countries submitted 2703 clinical isolates (2301 [85%] K pneumoniae and 402 (15%) E coli). 850 (37%) of 2301 K pneumoniae samples and 77 (19%) of 402 E coli samples were carbapenemase (KPC, NDM, OXA-48-like, or VIM) producers. The ratio of K pneumoniae to E coli was 11:1. 1·3 patients per 10000 hospital admissions had positive clinical specimens. Prevalence differed greatly, with the highest rates in Mediterranean and Balkan countries. Carbapenemase-producing K pneumoniae isolates showed high resistance to last-line antibiotics. INTERPRETATION: This initiative shows an encouraging commitment by all participants, and suggests that challenges in the establishment of a continent-wide enhanced sentinel surveillance for carbapenemase-producing Enterobacteriaeceae can be overcome. Strengthening infection control efforts in hospitals is crucial for controlling spread through local and national health care networks. FUNDING: European Centre for Disease Prevention and Control.
AU  - Grundmann,H
AU  - Glasner,C
AU  - Albiger,B
AU  - Aanensen,DM
AU  - Tomlinson,CT
AU  - Andrasevi,AT
AU  - Cantón,R
AU  - Carmeli,Y
AU  - Friedrich,AW
AU  - Giske,CG
AU  - Glupczynski,Y
AU  - Gniadkowski,M
AU  - Livermore,DM
AU  - Nordmann,P
AU  - Poirel,L
AU  - Rossolini,GM
AU  - Seifert,H
AU  - Vatopoulos,A
AU  - Walsh,T
AU  - Woodford,N
AU  - Monnet,DL
AU  - European,Survey of Carbapenemase-Producing Enterobacteriaceae EuSCAPE Working Group
DO  - 10.1016/S1473-3099(16)30257-2
EP  - 163
PY  - 2017///
SP  - 153
TI  - Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.
T2  - Lancet Infect Dis
UR  - http://dx.doi.org/10.1016/S1473-3099(16)30257-2
UR  - https://www.ncbi.nlm.nih.gov/pubmed/27866944
VL  - 17
ER  -

Download

DrDavidAanensen

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)